![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AstraZeneca’s Farxiga Falters in Phase 3 COVID-19 Trial
AstraZeneca’s Farxiga Falters in Phase 3 COVID-19 Trial
AstraZeneca’s heart failure and diabetes drug Farxiga (dapagliflozin) failed to meaningfully reduce the risk of organ dysfunction and death for high-risk, hospitalized COVID-19 patients in a phase 3 study.
Launched in April 2020, the trial was the first to assess the safety and efficacy of a sodium-glucose co-transporter-2 (SGLT2) inhibitor for hospitalized COVID-19 patients at risk of developing serious complications.
The global study, which enrolled 1,250 volunteers for a 30-day course of treatment, aimed to show if the drug would help treat co-morbidities like heart, kidney or metabolic conditions exacerbated by COVID-19.
AstraZeneca will share the full trial results next month.
Upcoming Events
-
18Jul
-
21Oct